GLP-1 receptor agonists have moved from specialized diabetes pharmacology to one of the most discussed categories in medicine in a short span of time. The clinical data on weight reduction, cardiovascular benefit, and metabolic improvement is substantial and, in some areas, substantial enough to change clinical practice. The commercial infrastructure that has grown around that data is more complicated.
Online prescribing platforms, medspas, and compounding pharmacies offering semaglutide and tirzepatide with minimal evaluation have proliferated faster than regulatory frameworks can keep up with them. Patients are arriving at medical practices with compounded injections they obtained with a questionnaire, without a baseline metabolic evaluation, without any physician who knows their history, and sometimes without clarity on what they are actually receiving. The clinical outcomes in those cases are unpredictable in ways the outcomes data from clinical trials was not.
What a physician actually evaluates before recommending a GLP-1 medication starts well before the prescription. Body composition is one part of the picture but not the only part. Baseline metabolic assessment — fasting insulin, hemoglobin A1c, a full lipid panel, hepatic markers, and kidney function — establishes where a patient actually sits metabolically and what the treatment is addressing. A patient who is insulin-resistant but not yet overtly diabetic and a patient who is post-menopausal with declining lean mass and increasing visceral fat may both benefit from GLP-1 therapy. They do not benefit in exactly the same way, and the monitoring and management strategy differs accordingly.
Cardiovascular history is essential. The clinical trial data that produced landmark cardiovascular benefit findings — reductions in major adverse cardiovascular events in high-risk populations — was generated in patients with established cardiovascular disease. The mechanism of benefit extends beyond weight reduction and includes direct cardiac and vascular effects. For patients with existing cardiovascular risk, that dimension of the medication’s profile is clinically important and changes how the treatment is framed. Dr. Stein’s approach to GLP-1 therapy integrates cardiovascular risk assessment from the beginning rather than treating it as a separate track.
Muscle mass preservation is the clinical concern that gets underweighted in the media coverage of these medications. GLP-1 therapy produces weight loss through caloric restriction, and caloric restriction without structured resistance training loses muscle alongside fat. Lean mass loss in a patient over 50 has consequences for metabolic rate, functional capacity, bone density, and long-term health that outlast the weight loss itself. A physician managing GLP-1 therapy without addressing protein intake, resistance training, and periodic body composition monitoring is managing one variable while eroding others. At Boca Raton Concierge Medicine, that conversation is part of the clinical management, not an afterthought.
Dosing and titration are more individualized than the protocols on most prescribing platforms suggest. Side effect profiles vary substantially between patients. Nausea, gastric emptying changes, and appetite suppression present differently in different individuals and respond differently to titration pace. The physician managing this process needs to be accessible — not available through a patient portal with a 48-hour response window, but reachable when a patient is nauseated four days into a dose increase and needs guidance on how to proceed. Direct physician access is not a peripheral feature in this context. It is the difference between a well-managed protocol and an abandoned one.
The question of compounded versus brand-name semaglutide and tirzepatide is one every physician in this space should address directly. The FDA has been clear that once a medication exits shortage status, compounded versions lose their legal basis for distribution. The pharmacological equivalence of compounded formulations has not been established in the same way as the approved products, and the regulatory environment around compounding practices continues to shift. Dr. Stein discusses these specifics with members who are evaluating GLP-1 therapy and provides guidance based on the current status of the medications and the member’s individual clinical situation.
The patients who see the best long-term outcomes from GLP-1 therapy are the ones who use the medication as one tool within a broader metabolic strategy. The medication creates a window. What happens in that window — the dietary pattern established, the exercise habit built, the metabolic health maintained — determines what the patient looks like five years after treatment rather than only while on it. That window management requires a physician relationship, not a prescribing platform. Chronic metabolic management at the depth this requires is built into the concierge model.
For members and prospective patients of our concierge medical doctors in Boca Raton evaluating GLP-1 therapy, the starting point is a comprehensive metabolic evaluation. The conversation about whether and how to proceed follows from that evaluation — not from a commercial platform’s screening algorithm. Call (561) 483-5500 or reach the practice through the contact page to discuss your situation directly with Dr. Stein.
The clinical evidence on GLP-1 medications continues to accumulate. The SURMOUNT-1 trial data published in the New England Journal of Medicine provides the foundational outcomes evidence for tirzepatide, including the cardiovascular and metabolic findings that go beyond body weight. Understanding that evidence is part of what a physician-guided conversation about these medications should include.